Press Release
SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today the opening of its recently acquired 100,000 square-foot warehouse and distribution facility in Memphis, Tennessee.
The facility, strategically located in the distribution hub of Memphis, enhances NuVasive's efficiency and responsiveness to customers. The facility provides ample working space for the processing of inventory and instruments, and the location near the Federal Express worldwide distribution hub affords additional working hours each day to process and ship products and instrument sets, including an ability to accept last-minute East Coast requests for loaner sets for surgical procedures.
Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "The purchase and opening of this facility is consistent with our culture of Absolute Responsiveness(R), which continues to be a major competitive advantage for NuVasive. The location of the facility near Federal Express's distribution center will support our expanding customer base, which is being driven by our exclusive sales force and new product launches."
About NuVasive
NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $2.9 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as classic fusion implants.
The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings -- NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R)-- that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's classic fusion portfolio is comprised predominantly of proprietary saline packaged bone allografts and internal fixation products. NuVasive also has a robust R&D pipeline emphasizing both MAS and motion preservation products.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward- looking statement to reflect events or circumstances arising after the date on which it was made.
Contact: Investors:
Kevin C. O'Boyle Stephanie Carrington/Nick Laudico
EVP & Chief Financial Officer The Ruth Group
NuVasive, Inc. 646-536-7017/7030
858-909-1800 scarrington@theruthgroup.com
investorrelations@nuvasive.com nlaudico@theruthgroup.com
SOURCE
NuVasive, Inc.
09/11/2006
CONTACT:
Kevin C. O'Boyle of NuVasive, Inc.,
EVP & Chief Financial
Officer,
1-858-909-1800, investorrelations@nuvasive.com,
or
Stephanie
Carrington,
1-646-536-7017, scarrington@theruthgroup.com,
or
Nick Laudico,
1-646-536-7030, nlaudico@theruthgroup.com,
both of The Ruth Group